Abstract
Mesenchymal stem cells (MSC) possess anti-inflammatory properties and participate in tissue repair. We used MSC to heal therapy-induced tissue toxicity. Ten consecutive patients, treated with MSC due to tissue toxicity following allogeneic hematopoietic stem cell transplantation, (ASCT) were included. Their median age was 48 (13–64) years. Seven had hemorrhagic cystitis grades 2–5, two had pneumomediastinum and one had perforated colon and peritonitis. MSC donors were mainly third-party, HLA-mismatched (n=11), HLA-haploidentical (n=3) and, in two cases, the HLA-identical ASCT sibling donors. MSC were given intravenously, the median cell dose was 1.0 (range 0.7–2) × 106/kg. In five patients, the severe hemorrhagic cystitis cleared after MSC infusion. Gross hematuria disappeared after median 3 (1–14) days. Two patients had reduced transfusion requirements after MSC infusion, but died of multiorgan failure. In one of them, MSC donor DNA was demonstrated in the urinary bladder. In two patients, pneumomediastinum disappeared after MSC infusions. A patient with steroid-resistant graft-versus-host disease of the gut experienced perforated diverticulitis and peritonitis that was reversed twice by MSC. MSC is a novel treatment for therapy-induced tissue toxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP . Heterotopic of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230–247.
Almeida-Porada G, Porada CD, Tran N, Zanjani ED . Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 2000; 95: 3620–3627.
Bruder SP, Fink DJ, Caplan AI . Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994; 56: 283–294.
Haynesworth SE, Goshima J, Goldberg VM, Caplan AI . Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13: 81–88.
Grande DA, Southerland SS, Manji R, Pate DW, Schwartz SE, Lucas PA . Repair of articular cartilage defects using mesenchymal stem cells. Tissue Eng 1995; 1: 345–353.
Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chiu RC . Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000; 120: 999–1005.
Young RG, Butler DL, Weber W, Gordon SL, Fink DJ . Mesenchymal stem cell-based repair of rabbit Achilles tendon. Trans Orthop Res Soc 1997; 22: 249.
Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48.
Le Blanc K, Ringden O . Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321–334.
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O . Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11–20.
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC . Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389–397.
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441.
Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390–1397.
Caplan AI . Mesenchymal stem cells. J Orthop Res 1991; 9: 641–650.
Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003; 5: 1028–1038.
Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI . The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12–20.
Olerup O, Zetterquist H . HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 h: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225–235.
Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293–298.
Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andstrom E et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619–625.
Remberger M, Svahn BM, Mattsson J, Ringden O . Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122–127.
Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328–336.
NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://ctep.cancer.gov/forms/CTCAEv3.pdf 2003.
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI . Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–564.
Koc ON, Lazarus HM . Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant 2001; 27: 235–239.
Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R . Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999–3001.
Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316.
Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932–8937.
Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13: 1103–1109.
Childs R, Sanchez C, Engler H, Preuss J, Rosenfeld S, Dunbar C et al. High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T-cell depletion and cyclosporine. Bone Marrow Transplant 1998; 22: 889–893.
Leung AY, Yuen KY, Kwong YL . Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant 2005; 36: 929–937.
Murphy GF, Wood Jr DP, McRoberts JW, Henslee-Downey PJ . Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol 1993; 149: 565–566.
Seber A, Shu XO, Defor T, Sencer S, Ramsay N . Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 1999; 23: 35–40.
Hassan Z, Remberger M, Svenberg P, Elbander M, Omazic B, Mattsson J et al. Hemorrhagic cystitis: a single center retrospective survey. Clin Transplant 2007, in press.
Ost L, Lonnqvist B, Eriksson L, Ljungman P, Ringden O . Hemorrhagic cystitis—a manifestation of graft versus host disease? Bone Marrow Transplant 1987; 2: 19–25.
Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn BM, Barkholt L et al. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 2006; 91: 401–404.
Garderet L, Bittencourt H, Sebe P, Kaliski A, Claisse JP, Esperou H et al. Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. Transplantation 2000; 70: 1807–1811.
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K . Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant 2006; 37: 1051–1059.
Tollemar J, Ringden O, Bostrom L, Nilsson B, Sundberg B . Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635–641.
Acknowledgements
We thank Maivor Hoglund-Lindecrantz for data collection and Inger Hammarberg for secretarial assistance. This study was supported by grants from the Swedish Cancer Society (0070-B02–16XAC, 4562-B02–02XBB), the Children's Cancer Foundation (2000/067, 01/039), the Swedish Research Council (K2003–32X-05971–23A, K2003–32XD-14716–01A), the Cancer Society in Stockholm, the Cancer- and Allergy Foundation, and Karolinska Institutet.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ringdén, O., Uzunel, M., Sundberg, B. et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 21, 2271–2276 (2007). https://doi.org/10.1038/sj.leu.2404833
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404833
Keywords
This article is cited by
-
Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs?
Journal of Translational Medicine (2024)
-
Mesenchymal stem cells limit vascular and epithelial damage and restore the impermeability of the urothelium in chronic radiation cystitis
Stem Cell Research & Therapy (2023)
-
A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation
European Journal of Medical Research (2023)
-
Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells
International Journal of Hematology (2020)
-
The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage
Stem Cell Reviews and Reports (2019)